- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01234051
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Goals
- The primary goal of this phase II trial is to:
evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy
Secondary goals are to:evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population
- Design
The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon.22
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Eun Ki Song
- Phone Number: +82-63-250-1245
- Email: eksong@jbnu.ac.kr
Study Contact Backup
- Name: Hwan Jung Yun
- Phone Number: +82-42-280-7157
- Email: hjyun@cnu.ac.kr
Study Locations
-
-
-
Chonbuk, Korea, Republic of
- Recruiting
- Eun Ki Song
-
Contact:
- Eun Ki Song
- Email: eksong@jbnu.ac.kr
-
Contact:
- Hwan Jung Yun
- Email: hjyun@cnu.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically
- Unresectable locally advanced, metastatic, or recurrent biliary tract cancer
- Patients must be ≥ 18 years old of age
- ECOG performance status ≤ 2 (see Appendix C)
- At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (see Appendix D)
- Estimated life expectancy of more than 3 months
- Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)
- Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN])
- Adequate liver function (serum total bilirubin < 3xULN; serum transaminases levels < 5xUNL)
- Provision of fully informed consent prior to any study specific procedures
Exclusion Criteria:
- Other tumor type than adenocarcinoma
- Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy)
- Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥5 years)
- Patients who received radiotherapy on target lesion within 6 months prior to study treatment
- Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases
- Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery
- Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception
- Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
- Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Docetaxel, oxaliplatin, palliative chemotherapy
|
1. Treatment Schedule 1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required. 1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate
Time Frame: 2years
|
2years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related toxicities
Time Frame: 2 years
|
Number and proportion of patients with adverse events according to the NCI-CTCAE (v 4.0) as a measure of treatment-related toxicities
|
2 years
|
Progression free survival
Time Frame: 2 years
|
Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves. The median PFS and OS will be used for measure. |
2 years
|
Overall survival
Time Frame: 2 years
|
Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves. The median PFS and OS will be used for measure. |
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eun Ki Song, Chonbuk National Universitiy Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KSWOG 2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Cancer
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Hospital de Cancer de Barretos - Fundacao Pio XIIUnknown
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingResectable Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
Clinical Trials on Docetaxel, Oxaliplatin
-
SanofiCompletedStomach NeoplasmsFrance, Russian Federation, Portugal, Spain, United States, Turkey, Belgium, Hungary, Italy, United Kingdom, Germany, Switzerland
-
University of PittsburghSanofiCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Samsung Medical CenterCompletedGastric CancerKorea, Republic of
-
GERCOR - Multidisciplinary Oncology Cooperative...Unknown
-
Fudan UniversityChinese Anti-Cancer AssociationAvailableTriple Negative Local Advanced Breast Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Johannes Gutenberg University MainzCompletedStomach Neoplasms | Esophageal NeoplasmsGermany
-
Oncology Specialists, S.C.Sanofi-SynthelaboTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Minneapolis Veterans Affairs Medical CenterSanofiTerminatedNeoplasms | Head and Neck NeoplasmsUnited States